COVID-19 Outpatient Study: Ridgeback Biotherapeutics, LP - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if the study medicine (EIDD-2801) can reduce the amount of virus in someone's body, improve symptoms, and reduce complications.

We are also looking at whether this medication will reduce the spread of the virus between people.

What is the Condition Being Studied?

COVID-19

Who Can Participate in the Study?

Adults that have:
-Developed symptoms for COVID-19 within 7 days of signing up for this study
-Experienced at least 1 symptom of COVID-19
-Are not in the hospital

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
-Be randomized (like flipping a coin) to Group 1 or Group 2:
--Group 1 will take the study medicine (EIDD-2801) for 5 days
--Group 2 will take a placebo (inactive study pill that does nothing) for 5 days

Both groups will:
-Give blood samples
-Have nasal swabs
-Take the study medicine
-Have either in-clinic or at-home visits during the 2 weeks you are infected with COVID-19

Study Details

Full Title
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety,Tolerability, and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2 Viral RNA Detection in Persons with COVID-19
Principal Investigator
Infectious Disease Specialist
Protocol Number
IRB: PRO00106857
NCT: NCT04405570
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698